SeV986A
Our group utilizes an replication-defective Sendai virus (SeV) as TB vaccine vector, and constructed SeV85AB and SeV986A vaccine. SeV986A expressed a fusion of acute- and latency-stage Mtb antigens (4 antigens). In murine models, it serves as a potent BCG-booster, significantly reducing bacterial burden in both active and latent infection challenges.
Read MoremRNA-Rv1387-Rv0287-Rv1788
The vaccine consists of three antigens delivered with the mRNA platform. Monovalent antigens were cloned into mRNA constructs containing a 5’ cap, 5’ untranslated region (UTR), 3’ UTR, and a polyadenylation signal, subjected to in vitro transcription using N1-methylpseudouridine, and encapsulated in lipid nanoparticles containing ALC-0315, 18:1 (Δ9-Cis) PE (DOPE), cholesterol, and 14:0 PEG2000 PE.
Read MorerBCG-LTAK63
rBCG-LTAK63 is an unmarked recombinant BCG strain expressing the subunit A of detoxified E. coli Heat-Labile Toxin (LTAK63) as adjuvant. rBCG-LTAK63 induced protection superior to standard BCG, through enhanced and regulated Th1/Th17 responses, and both early effector and long-term TRM cell responses with reduced lung inflammation and improved immunopathological control.
Read MoreAd5Ag85A*
Ad5Ag85A is a human adenovirus serotype 5-vectored vaccine expressing Antigen 85A (Ag85A). This vaccine is delivered by the inhaled aerosol route.
Read MoreChAdOx1.5Ag/MVA.5Ag
ChAdOx1.5Ag is a recombinant, replication deficient chimpanzee adenovirus, expressing the four antigens of the mycobacterium Esx-5a system (PPE15, PE8, EsxI, EsxJ), along with Ag85A. In mice, ChAdOx1.5Ag improved the efficacy of BCG in the lung and spleen, and a further boost with MVA.5Ag further improved efficacy in the spleen. ChAdOx1.5Ag/MVA.5Ag was also promising in non-human…
Read More